439 related articles for article (PubMed ID: 21875160)
1. Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.
Kirson NY; Birnbaum HG; Ivanova JI; Waldman T; Joish V; Williamson T
Appl Health Econ Health Policy; 2011 Sep; 9(5):293-303. PubMed ID: 21875160
[TBL] [Abstract][Full Text] [Related]
2. Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.
Kirson NY; Birnbaum HG; Ivanova JI; Waldman T; Joish V; Williamson T
Appl Health Econ Health Policy; 2011 Nov; 9(6):377-87. PubMed ID: 21888449
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States.
Kirson NY; Birnbaum HG; Ivanova JI; Waldman T; Joish V; Williamson T
Curr Med Res Opin; 2011 Sep; 27(9):1763-8. PubMed ID: 21793646
[TBL] [Abstract][Full Text] [Related]
4. The cost to managed care of managing pulmonary hypertension.
Said Q; Martin BC; Joish VN; Kreilick C; Mathai SC
J Med Econ; 2012; 15(3):500-8. PubMed ID: 22313330
[TBL] [Abstract][Full Text] [Related]
5. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
6. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States.
Copher R; Cerulli A; Watkins A; Laura Monsalvo M
J Med Econ; 2012; 15(5):947-55. PubMed ID: 22554140
[TBL] [Abstract][Full Text] [Related]
7. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
8. Characterizing pulmonary hypertension-related hospitalization costs among Medicare Advantage or commercially insured patients with pulmonary arterial hypertension: a retrospective database study.
Burke JP; Hunsche E; RĂ©gulier E; Nagao M; Buzinec P; Drake Iii W
Am J Manag Care; 2015 Jan; 21(3 Suppl):s47-58. PubMed ID: 25734573
[TBL] [Abstract][Full Text] [Related]
9. Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States.
Ivanova JI; Birnbaum HG; Kidolezi Y; Qiu Y; Mallett D; Caleo S
Epilepsia; 2010 May; 51(5):838-44. PubMed ID: 20002150
[TBL] [Abstract][Full Text] [Related]
10. Economic burden and co-morbidities of atrial fibrillation in a privately insured population.
Wu EQ; Birnbaum HG; Mareva M; Tuttle E; Castor AR; Jackman W; Ruskin J
Curr Med Res Opin; 2005 Oct; 21(10):1693-9. PubMed ID: 16238910
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States.
Angalakuditi M; Edgell E; Beardsworth A; Buysman E; Bancroft T
J Med Econ; 2010; 13(3):393-402. PubMed ID: 20608882
[TBL] [Abstract][Full Text] [Related]
12. Healthcare cost attributable to recently-diagnosed breast cancer in a privately-insured population in the United States.
Fu AZ; Jhaveri M
J Med Econ; 2012; 15(4):688-94. PubMed ID: 22397589
[TBL] [Abstract][Full Text] [Related]
13. Direct and indirect costs associated with Dupuytren's contracture.
Macaulay D; Ivanova J; Birnbaum H; Sorg R; Skodny P
J Med Econ; 2012; 15(4):664-71. PubMed ID: 22369346
[TBL] [Abstract][Full Text] [Related]
14. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis.
Pelletier EM; Shim B; Goodman S; Amonkar MM
Breast Cancer Res Treat; 2008 Mar; 108(2):297-305. PubMed ID: 17577662
[TBL] [Abstract][Full Text] [Related]
16. Early retirement and income loss in patients with early and advanced Parkinson's disease.
Johnson S; Davis M; Kaltenboeck A; Birnbaum H; Grubb E; Tarrants M; Siderowf A
Appl Health Econ Health Policy; 2011 Nov; 9(6):367-76. PubMed ID: 21919541
[TBL] [Abstract][Full Text] [Related]
17. Costs associated with attempted suicide among individuals with bipolar disorder.
Stensland MD; Zhu B; Ascher-Svanum H; Ball DE
J Ment Health Policy Econ; 2010 Jun; 13(2):87-92. PubMed ID: 20919595
[TBL] [Abstract][Full Text] [Related]
18. Cost of heart failure among hypertensive users of nonspecific NSAIDs and COX-2-specific inhibitors.
Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
Am J Manag Care; 2002 Oct; 8(15 Suppl):S414-27. PubMed ID: 12416791
[TBL] [Abstract][Full Text] [Related]
19. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
20. Estimates of the direct cost per case and overall burden of trichomoniasis for the employer-sponsored privately insured women population in the United States, 2001 to 2005.
Owusu-Edusei K; Tejani MN; Gift TL; Kent CK; Tao G
Sex Transm Dis; 2009 Jun; 36(6):395-9. PubMed ID: 19556934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]